BRAF and colorectal carcinoma: For example, 40–45% of CRC patients harbor KRAS, 5–7% NRAS, and even fewer HRAS mutations while 7–15% harbor BRAF mutations, resulting in constitutive activation of the RAS/MAPK/ERK pathway [18].